Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24758997 | 0.86 | — | — | |
| SCHEMBL30141544 | 0.83 | MAPT (0.34) | KMT2AKDM4EMAPTPOLBHPGD | |
| SCHEMBL30976021 | 0.77 | LMNA (0.36) | KMT2AKDM4EMAPTPOLBHPGD | |
| SCHEMBL30141501 | 0.76 | KDM4E (0.36) | KMT2AKDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL30951783 | 0.75 | LMNA (0.33) | KDM4EMAPTHPGDALDH1A1LMNA | |
| SCHEMBL30951782 | 0.75 | LMNA (0.33) | KDM4EMAPTHPGDALDH1A1LMNA | |
| SCHEMBL24906332 | 0.75 | LMNA (0.33) | KDM4EMAPTHPGDALDH1A1LMNA | |
| SCHEMBL27243079 | 0.74 | KDM4E (0.33) | KMT2AKDM4EMAPTPOLBHPGD | |
| SCHEMBL24906279 | 0.72 | KDM4E (0.35) | KMT2AKDM4EMAPTPOLBHPGD | |
| SCHEMBL30976103 | 0.71 | KDM4E (0.33) | KMT2AKDM4EMAPTPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | KMT2A 2357/4885KDM4E 2803/4885MAPT 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.